Silverback Therapeutics has revealed that Laura Shawver, fresh from taking Synthorx through a $2.5bn acquisition by Sanofi, will take the reins at the company.
Shawver arrives with plenty of experience leading similar sized biotech, after having previously held the role of CEO at Cleave Biosciences and Phenomix Corporation.
Silverback is working on immunotherapies within oncology, fibrosis and virology, with the biotech expected to enter clinical trials with its lead immuno-oncology candidate, SBT6050, in the second half of 2020.
Shawver said, “Marrying the curative potential of IO treatment with the precision of targeted drugs is a major advancement. I look forward to marshalling the necessary resources to maximize the value of the ImmunoTAC platform for all the stakeholders.”